Citadel Advisors’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-27,170
| Closed | -$3.79M | – | 8449 |
|
|
2017
Q2 | $2.82M | Sell |
27,170
-300,198
| -92% | -$24.5M | ﹤0.01% | 2739 |
|
|
2017
Q1 | $25.7M | Buy |
327,368
+318,730
| +3,690% | +$19.7M | 0.02% | 805 |
|
|
2016
Q4 | $387K | Sell |
8,638
-29,719
| -77% | -$1.46M | ﹤0.01% | 5302 |
|
|
2016
Q3 | $2.14M | Sell |
38,357
-151,596
| -80% | -$8.45M | ﹤0.01% | 2893 |
|
|
2016
Q2 | $9.5M | Sell |
189,953
-562,395
| -75% | -$27.6M | 0.01% | 1289 |
|
|
2016
Q1 | $34.5M | Buy |
752,348
+193,029
| +35% | +$9.35M | 0.04% | 449 |
|
|
2015
Q4 | $34.5M | Buy |
559,319
+559,318
| +55,931,800% | +$39.4M | 0.04% | 558 |
|
|
2015
Q3 | $0 | Sell |
1
-2,567
| -100% | -$161K | ﹤0.01% | 9472 |
|
|
2015
Q2 | $157K | Sell |
2,568
-16,781
| -87% | -$957K | ﹤0.01% | 6617 |
|
|
2015
Q1 | $1.12M | Sell |
19,349
-52,148
| -73% | -$3.49M | ﹤0.01% | 3780 |
|
|
2014
Q4 | $4.12M | Buy |
71,497
+43,240
| +153% | +$1.82M | ﹤0.01% | 2154 |
|
|
2014
Q3 | $805K | Sell |
28,257
-10,881
| -28% | -$269K | ﹤0.01% | 3990 |
|
|
2014
Q2 | $1.13M | Buy |
+39,138
| New | +$1.17M | ﹤0.01% | 3344 |
|
Citadel Advisors's KITE Position: Q3 2017 in Review
Citadel Advisors sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 27,170 shares — an estimated $3.79M sold.
Citadel Advisors first reported a position in KITE in Q2 2014 and held it in 13 quarters. The position peaked at $34.5M in Q1 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.
- Citadel Advisors reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
- Citadel Advisors sold 27,170 Kite Pharma, Inc. shares in Q3 2017, an estimated $3.79M.
- Citadel Advisors first reported a position in Kite Pharma, Inc. in Q2 2014 and held it in 13 quarters.
- Citadel Advisors's Kite Pharma, Inc. position peaked at $34.5M in Q1 2016.
- 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.
Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.